418 results on '"Brullo, Chiara"'
Search Results
152. Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1 Adenosine Receptors
- Author
-
Manetti, Fabrizio, primary, Schenone, Silvia, additional, Bondavalli, Francesco, additional, Brullo, Chiara, additional, Bruno, Olga, additional, Ranise, Angelo, additional, Mosti, Luisa, additional, Menozzi, Giulia, additional, Fossa, Paola, additional, Trincavelli, Maria Letizia, additional, Martini, Claudia, additional, Martinelli, Adriano, additional, Tintori, Cristina, additional, and Botta, Maurizio, additional
- Published
- 2005
- Full Text
- View/download PDF
153. Synthesis and Biological Evaluation of Neutrophilic Inflammation Inhibitors.
- Author
-
Bruno, Olga, primary, Brullo, Chiara, additional, Arduino, Nicoletta, additional, Schenone, Silvia, additional, Ranise, Angelo, additional, Bondavalli, Francesco, additional, Ottonello, Luciano, additional, Dapino, Patrizia, additional, and Dallegri, Franco, additional
- Published
- 2004
- Full Text
- View/download PDF
154. Pyrazolo[3,4-d]pyrimidines Endowed with Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells
- Author
-
Carraro, Fabio, primary, Pucci, Annalisa, additional, Naldini, Antonella, additional, Schenone, Silvia, additional, Bruno, Olga, additional, Ranise, Angelo, additional, Bondavalli, Francesco, additional, Brullo, Chiara, additional, Fossa, Paola, additional, Menozzi, Giulia, additional, Mosti, Luisa, additional, Manetti, Fabrizio, additional, and Botta, Maurizio, additional
- Published
- 2004
- Full Text
- View/download PDF
155. Synthesis and pharmacological evaluation of 5H-[1]benzopyrano[4,3-d]pyrimidines effective as antiplatelet/analgesic agents
- Author
-
Bruno, Olga, primary, Brullo, Chiara, additional, Schenone, Silvia, additional, Bondavalli, Francesco, additional, Ranise, Angelo, additional, Tognolini, Massimiliano, additional, Ballabeni, Vigilio, additional, and Barocelli, Elisabetta, additional
- Published
- 2004
- Full Text
- View/download PDF
156. 2‐Aryl‐3‐phenylamino‐4,5‐dihydro‐2H‐benz[g]indazoles with Analgesic Activity.
- Author
-
Schenone, Silvia, primary, Bruno, Olga, additional, Ranise, Angelo, additional, Brullo, Chiara, additional, Bondavalli, Francesco, additional, Filippelli, Walter, additional, Mazzeo, Filomena, additional, Capuano, Annalisa, additional, and Falcone, Giuseppe, additional
- Published
- 2003
- Full Text
- View/download PDF
157. Progress in 5H[1]Benzopyrano[4,3‐d]pyrimidin‐5‐amine Series: 2‐Methoxy Derivatives Effective as Antiplatelet Agents with Analgesic Activity.
- Author
-
Bruno, Olga, primary, Brullo, Chiara, additional, Schenone, Silvia, additional, Ranise, Angelo, additional, Bondavalli, Francesco, additional, Barocelli, Elisabetta, additional, Tognolini, Massimiliano, additional, Magnanini, Francesca, additional, and Ballabeni, Vigilio, additional
- Published
- 2003
- Full Text
- View/download PDF
158. Progress in 5H[1]benzopyrano[4,3-d]pyrimidin-5-amine series: 2-methoxy derivatives effective as antiplatelet agents with analgesic activity
- Author
-
Bruno, Olga, primary, Brullo, Chiara, additional, Schenone, Silvia, additional, Ranise, Angelo, additional, Bondavalli, Francesco, additional, Barocelli, Elisabetta, additional, Tognolini, Massimiliano, additional, Magnanini, Francesca, additional, and Ballabeni, Vigilio, additional
- Published
- 2002
- Full Text
- View/download PDF
159. Synthesis, Biological Evaluation,and Molecular Modelingof New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) RelatedPhosphodiesterase 4D (PDE4D) Inhibitors.
- Author
-
Brullo, Chiara, Massa, Matteo, Rocca, Massimo, Rotolo, Chiara, Guariento, Sara, Rivera, Daniela, Ricciarelli, Roberta, Fedele, Ernesto, Fossa, Paola, and Bruno, Olga
- Subjects
- *
BENZALDEHYDE , *OXIMES , *CHEMICAL synthesis , *PHOSPHODIESTERASE inhibitors , *FUNCTIONAL groups , *ANTINEOPLASTIC agents , *MOLECULAR models , *THERAPEUTICS - Abstract
A new series of 3-(cyclopentyloxy)-4-methoxyphenylderivatives,structurally related to our hit GEBR-4a (1) and GEBR-7b(2), has been designed by changing length and functionalityof the chain linking the catecholic moiety to the terminal cycloamineportion. Among the numerous molecules synthesized, compounds 8, 10a, and 10bshowed increasedpotency as PDE4D enzyme inhibitors with respect to 2anda good selectivity against PDE4A4, PDE4B2, and PDE4C2 enzymes, withoutboth cytotoxic and genotoxic effects. The ability to enhance cAMPlevel in neuronal cells was assessed for compound 8.SAR considerations, also confirmed by in silico docking simulations,evidenced that both chain and amino terminal function characterizedby higher hydrophilicity are required for a good and selective inhibitor–catalyticpocket interaction. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
160. Design,Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant.
- Author
-
Radi, Marco, Tintori, Cristina, Musumeci, Francesca, Brullo, Chiara, Zamperini, Claudio, Dreassi, Elena, Fallacara, Anna Lucia, Vignaroli, Giulia, Crespan, Emmanuele, Zanoli, Samantha, Laurenzana, Ilaria, Filippi, Irene, Maga, Giovanni, Schenone, Silvia, Angelucci, Adriano, and Botta, Maurizio
- Published
- 2013
- Full Text
- View/download PDF
161. Vascular Endothelial GrowthFactor (VEGF) Receptors: Drugs and New Inhibitors.
- Author
-
Musumeci, Francesca, Radi, Marco, Brullo, Chiara, and Schenone, Silvia
- Published
- 2012
- Full Text
- View/download PDF
162. Pyrazole-Based Water-Soluble Dendrimer Nanoparticles as a Potential New Agent against Staphylococci.
- Author
-
Alfei, Silvana, Brullo, Chiara, Caviglia, Debora, Piatti, Gabriella, Zorzoli, Alessia, Marimpietri, Danilo, Zuccari, Guendalina, and Schito, Anna Maria
- Subjects
STAPHYLOCOCCAL diseases ,STAPHYLOCOCCUS ,SKIN infections ,NANOPARTICLES ,ANTIBACTERIAL agents ,GRAM-positive bacteria ,MICROCOCCACEAE - Abstract
Although the antimicrobial potency of the pyrazole nucleus is widely reported, the antimicrobial effects of the 2-(4-bromo-3,5-diphenyl-pyrazol-1-yl)-ethanol (BBB4), found to be active against several other conditions, have never been investigated. Considering the worldwide need for new antimicrobial agents, we thought it noteworthy to assess the minimum inhibitory concentration (MICs) of BBB4 but, due to its scarce water-solubility, unequivocal determinations were tricky. To obtain more reliable MICs and to obtain a substance also potentially applicable in vivo, we recently prepared water-soluble, BBB4-loaded dendrimer nanoparticles (BBB4-G4K NPs), which proved to have physicochemical properties suitable for clinical application. Here, with the aim of developing a new antibacterial agent based on BBB4, the BBB4-G4K NPs were tested on several strains of different species of the Staphylococcus genus. Very low MICs (1.5–3.0 µM), 15.5–124.3-fold lower than those of the free BBB4, were observed against several isolates of S. aureus and S. epidermidis, the most pathogenic species of this genus, regardless of their resistance patterns to antibiotics. Aiming at hypothesizing a clinical use of BBB4-G4K NPs for staphylococcal skin infections, cytotoxicity experiments on human keratinocytes were performed; it was found that the nano-manipulated BBB4 released from BBB4-G4K NPs (LD
50 138.6 µM) was 2.5-fold less cytotoxic than the untreated BBB4 (55.9 µM). Due to its physicochemical and biological properties, BBB4-G4K NPs could be considered as a promising novel therapeutic option against the very frequent staphylococcal skin infections. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
163. Substituted Pyrazolo[3,4- b]pyridines as Potent A1 Adenosine Antagonists: Synthesis, Biological Evaluation, and Development of an A1 Bovine Receptor Model.
- Author
-
Tuccinardi, Tiziano, Schenone, Silvia, Bondavalli, Francesco, Brullo, Chiara, Bruno, Olga, Mosti, Luisa, Zizzari, Alessandra Tania, Tintori, Cristina, Manetti, Fabrizio, Ciampi, Osele, Trincavelli, Maria Letizia, Martini, Claudia, Martinelli, Adriano, and Botta, Maurizio
- Published
- 2008
- Full Text
- View/download PDF
164. Synthesis and biological evaluation of neutrophilic inflammation inhibitors
- Author
-
Bruno, Olga, Brullo, Chiara, Arduino, Nicoletta, Schenone, Silvia, Ranise, Angelo, Bondavalli, Francesco, Ottonello, Luciano, Dapino, Patrizia, and Dallegri, Franco
- Subjects
- *
DISEASES , *NEUTROPHILS , *PROTEIN kinases , *TUMOR necrosis factors , *RHEUMATOID arthritis , *OBSTRUCTIVE lung diseases - Abstract
In several non-infectious human diseases, such as ulcerous colitis, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), the extravasal recruitment of neutrophils plays a crucial role in the development of tissue damage, which, when persistent, can lead to the irreversible organ dysfunction. The neutrophil activation is controlled by a number of intracellular pathways, particularly by a cAMP-dependent protein kinase A (PKA) which also acts on phosphodiesterase IV (PDE4) gene stimulating the synthesis of this enzyme, able to transform cAMP to inactive AMP. PDE4 inhibitors enhance intracellular cAMP and decrease inflammatory cell activation. Several 3-cyclopentyloxy-4-methoxybenzaldehyde and 3-cyclopentyloxy-4-methoxybenzoic acid derivatives were synthesized and studied by us to evaluate their ability to inhibit the superoxide anion production in human neutrophils. These compounds were found able to inhibit the neutrophil activation and some of them increased the cAMP level on tumor necrosis factor-α-stimulated neutrophils. Moreover, they also inhibited selectively the human PDE4 enzyme, although they are less potent than the reference compound Rolipram. We report here synthesis, biological studies and some SAR considerations concerning the above mentioned compounds. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
165. Combined Effects of Methyldopa and Flavonoids on the Expression of Selected Factors Related to Inflammatory Processes and Vascular Diseases in Human Placenta Cells—An In Vitro Study.
- Author
-
Bogacz, Anna, Mikołajczak, Przemysław Ł., Wolek, Marlena, Górska, Aleksandra, Szulc, Michał, Ożarowski, Marcin, Kujawski, Radosław, Czerny, Bogusław, Wolski, Hubert, Karpiński, Tomasz M., Seremak-Mrozikiewicz, Agnieszka, and Brullo, Chiara
- Abstract
The aim of the study was to investigate combined effects of flavonoids (apigenin, baicalein, chrysin, quercetin, and scutellarin) and methyldopa on the expression of selected proinflammatory and vascular factors in vitro for prediction of their action in pregnancy-induced hypertension. The research was conducted on a trophoblast-derived human choriocarcinoma cell line and a primary human umbilical vein endothelial cell line. Cytotoxicity of compounds in selected concentrations (20, 40, and 100 µmol) was measured using the MTT test and the concentration of 40 µmol was selected for further analysis. Subsequently, their effects with methyldopa on the expression of selected markers responsible for inflammation (TNF-α; IL-1β; IL-6) and vascular effects (hypoxia-inducible factor 1α—HIF-1α; placental growth factor—PIGF; transforming growth factor β—TGF-β; vascular endothelial growth factor—VEGF) at the mRNA and protein levels were assessed. It was found that every combined administration of a flavonoid and methyldopa in these cells induced a down-regulating effect on all tested factors, except PIGF, especially at the mRNA expression level. As hypertension generally raises TNF-α, IL-1β, IL-6, HIF-1α, TGF-β, and VEGF mRNA expression and/or protein levels, the results obtained in the studied model may provide a positive prognostic factor for such activity in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
166. Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents.
- Author
-
J. Solum, Eirik, Liekens, Sandra, Hansen, Trond Vidar, Brullo, Chiara, and Tasso, Bruno
- Subjects
BIOSYNTHESIS ,ANTINEOPLASTIC agents ,HELA cells ,ENDOTHELIAL cells ,CELL lines - Abstract
The synthesis, cytotoxicity and inhibition of CDK8 by thirteen analogs of cortistatin A are reported. These efforts revealed that the analogs with either a 6- or 7-isoquinoline or 5-indole side chain in the 17-position are the most promising anti-proliferative agents. These compounds showed potent cytotoxic effects in CEM, HeLa and HMEC-1 cells. All three compounds exhibited IC
50 values < 10µM. The most interesting 10l analog exhibited an IC50 value of 0.59 µM towards the human dermal microvascular endothelial cell line (HMEC-1), significantly lower than the reference standard 2-methoxyestradiol. At a concentration at 50 nM the most potent 10h compound reduced the activity of CDK8 to 35%. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
167. Effects of Pyrrole-Imidazole Polyamides Targeting Human TGF-β1 on the Malignant Phenotypes of Liver Cancer Cells.
- Author
-
Takagi, Keiko, Midorikawa, Yutaka, Takayama, Tadatoshi, Abe, Hayato, Fujiwara, Kyoko, Soma, Masayoshi, Nagase, Hiroki, Miki, Toshio, Fukuda, Noboru, and Brullo, Chiara
- Subjects
LIVER cells ,LIVER cancer ,CANCER cells ,CANCER stem cells ,TRANSFORMING growth factors ,EPITHELIAL-mesenchymal transition ,POLYAMIDES - Abstract
Synthetic pyrrole-imidazole (PI) polyamides bind to the minor groove of double-helical DNA with high affinity and specificity, and inhibit the transcription of corresponding genes. In liver cancer, transforming growth factor (TGF)-β expression is correlated with tumor grade, and high-grade liver cancer tissues express epithelial-mesenchymal transition markers. TGF-β1 was reported to be involved in cancer development by transforming precancer cells to cancer stem cells (CSCs). This study aimed to evaluate the effects of TGF-β1-targeting PI polyamide on the growth of liver cancer cells and CSCs and their TGF-β1 expression. We analyzed TGF-β1 expression level after the administration of GB1101, a PI polyamide that targets human TGF-β1 promoter, and examined its effects on cell proliferation, invasiveness, and TGF-β1 mRNA expression level. GB1101 treatment dose-dependently decreased TGF-β1 mRNA levels in HepG2 and HLF cells, and inhibited HepG2 colony formation associated with downregulation of TGF-β1 mRNA. Although GB1101 did not substantially inhibit the proliferation of HepG2 cells compared to untreated control cells, GB1101 significantly suppressed the invasion of HLF cells, which displayed high expression of CD44, a marker for CSCs. Furthermore, GB1101 significantly inhibited HLF cell sphere formation by inhibiting TGF-β1 expression, in addition to suppressing the proliferation of HLE and HLF cells. Taken together, GB1101 reduced TGF-β1 expression in liver cancer cells and suppressed cell invasion; therefore, GB1101 is a novel candidate drug for the treatment of liver cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
168. Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole.
- Author
-
Czarnomysy, Robert, Radomska, Dominika, Muszyńska, Anna, Hermanowicz, Justyna Magdalena, Prokop, Izabela, Bielawska, Anna, Bielawski, Krzysztof, Brullo, Chiara, and Tasso, Bruno
- Subjects
TRANSITION metal complexes ,EPITHELIAL cell tumors ,MEMBRANE potential ,TUMOR growth ,BREAST cancer - Abstract
Novel transition metal complexes (Au, Pd, Pt) with berenil and 2-(1-methyl-5-nitroimidazol-2-yl)ethanol were obtained through two-step synthesis. The cytotoxicity assay against MCF-7 and MDA-MB-231 breast cancer cells revealed that novel platinum and palladium complexes cause a reduction on the viability of MCF-7 and MDA-MB-231 breast cancer cells to a greater extent than cisplatin. The complexes showed lower cytotoxicity on normal MCF-10A human breast epithelial cells than on tumor cells. Furthermore, we observed that these complexes selectively concentrate in tumor cell mitochondria due to the characteristic for these cells increased membrane potential that may explain their increased proapoptotic activity. The activity of the synthesized compounds against topoisomerase type IIα and their increased impact on DNA defragmentation also were documented. The novel complexes also induced autophagosome changes and inhibited tumor growth in xenograft models (established using breast cancer cells). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
169. Imidazo-Pyrazole-Loaded Palmitic Acid and Polystyrene-Based Nanoparticles: Synthesis, Characterization and Antiproliferative Activity on Chemo-Resistant Human Neuroblastoma Cells.
- Author
-
Valenti, Giulia Elda, Marengo, Barbara, Milanese, Marco, Zuccari, Guendalina, Brullo, Chiara, Domenicotti, Cinzia, and Alfei, Silvana
- Subjects
- *
IMIDAZOPYRIDINES , *PALMITIC acid , *NEUROBLASTOMA , *FOURIER transform infrared spectroscopy , *POTENTIOMETRY , *CHILDHOOD cancer , *NANOPARTICLES - Abstract
Neuroblastoma (NB) is a childhood cancer, commonly treated with drugs, such as etoposide (ETO), whose efficacy is limited by the onset of resistance. Here, aiming at identifying new treatments for chemo-resistant NB, the effects of two synthesized imidazo-pyrazoles (IMPs) (4G and 4I) were investigated on ETO-sensitive (HTLA-230) and ETO-resistant (HTLA-ER) NB cells, detecting 4I as the more promising compound, that demonstrated IC50 values lower than those of ETO on HTLA ER. Therefore, to further improve the activity of 4I, we developed 4I-loaded palmitic acid (PA) and polystyrene-based (P5) cationic nanoparticles (P5PA-4I NPs) with high drug loading (21%) and encapsulation efficiency (97%), by a single oil-in-water emulsification technique. Biocompatible PA was adopted as an emulsion stabilizer, while synthesized P5 acted as an encapsulating agent, solubilizer and hydrophilic–lipophilic balance (HLB) improver. Optic microscopy and cytofluorimetric analyses were performed to investigate the micromorphology, size and complexity distributions of P5PA-4I NPs, which were also structurally characterized by chemometric-assisted Fourier transform infrared spectroscopy (FTIR). Potentiometric titrations allowed us to estimate the milliequivalents of PA and basic nitrogen atoms present in NPs. P5PA-4I NPs afforded dispersions in water with excellent buffer capacity, essential to escape lysosomal degradation and promote long residence time inside cells. They were chemically stable in an aqueous medium for at least 40 days, while in dynamic light scattering (DLS) analyses, P5PA-4I showed a mean hydrodynamic diameter of 541 nm, small polydispersity (0.194), and low positive zeta potentials (+8.39 mV), assuring low haemolytic toxicity. Biological experiments on NB cells, demonstrated that P5PA-4I NPs induced ROS-dependent cytotoxic effects significantly higher than those of pristine 4I, showing a major efficacy compared to ETO in reducing cell viability in HTLA-ER cells. Collectively, this 4I-based nano-formulation could represent a new promising macromolecular platform to develop a new delivery system able to increase the cytotoxicity of the anticancer drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
170. Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology.
- Author
-
Paes, Dean, Schepers, Melissa, Willems, Emily, Rombaut, Ben, Tiane, Assia, Solomina, Yevgeniya, Tibbo, Amy, Blair, Connor, Kyurkchieva, Elka, Baillie, George S., Ricciarelli, Roberta, Brullo, Chiara, Fedele, Ernesto, Bruno, Olga, van den Hove, Daniel, Vanmierlo, Tim, and Prickaerts, Jos
- Abstract
Inhibition of phosphodiesterase 4D (PDE4D) enzymes has been investigated as therapeutic strategy to treat memory problems in Alzheimer’s disease (AD). Although PDE4D inhibitors are effective in enhancing memory processes in rodents and humans, severe side effects may hamper their clinical use. PDE4D enzymes comprise different isoforms, which, when targeted specifically, can increase treatment efficacy and safety. The function of PDE4D isoforms in AD and in molecular memory processes per se has remained unresolved. Here, we report the upregulation of specific PDE4D isoforms in transgenic AD mice and hippocampal neurons exposed to amyloid-β. Furthermore, by means of pharmacological inhibition and CRISPR-Cas9 knockdown, we show that the long-form PDE4D3, -D5, -D7, and -D9 isoforms regulate neuronal plasticity and convey resilience against amyloid-β in vitro. These results indicate that isoform-specific, next to non-selective, PDE4D inhibition is efficient in promoting neuroplasticity in an AD context. Therapeutic effects of non-selective PDE4D inhibitors are likely achieved through actions on long isoforms. Future research should identify which long PDE4D isoforms should be specifically targeted in vivo to both improve treatment efficacy and reduce side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
171. Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors.
- Author
-
Scarano, Naomi, Abbotto, Elena, Musumeci, Francesca, Salis, Annalisa, Brullo, Chiara, Fossa, Paola, Schenone, Silvia, Bruzzone, Santina, and Cichero, Elena
- Subjects
- *
CHEMICAL libraries , *SIRTUINS , *DEACETYLASES - Abstract
Sirtuin isoform 2 (SIRT2) is one of the seven sirtuin isoforms present in humans, being classified as class III histone deacetylases (HDACs). Based on the high sequence similarity among SIRTs, the identification of isoform selective modulators represents a challenging task, especially for the high conservation observed in the catalytic site. Efforts in rationalizing selectivity based on key residues belonging to the SIRT2 enzyme were accompanied in 2015 by the publication of the first X-ray crystallographic structure of the potent and selective SIRT2 inhibitor SirReal2. The subsequent studies led to different experimental data regarding this protein in complex with further different chemo-types as SIRT2 inhibitors. Herein, we reported preliminary Structure-Based Virtual Screening (SBVS) studies using a commercially available library of compounds to identify novel scaffolds for the design of new SIRT2 inhibitors. Biochemical assays involving five selected compounds allowed us to highlight the most effective chemical features supporting the observed SIRT2 inhibitory ability. This information guided the following in silico evaluation and in vitro testing of further compounds from in-house libraries of pyrazolo-pyrimidine derivatives towards novel SIRT2 inhibitors (1–5). The final results indicated the effectiveness of this scaffold for the design of promising and selective SIRT2 inhibitors, featuring the highest inhibition among the tested compounds, and validating the applied strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
172. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
- Author
-
Musumeci, Francesca, Fallacara, Anna Lucia, Brullo, Chiara, Grossi, Giancarlo, Botta, Lorenzo, Calandro, Pierpaolo, Chiariello, Mario, Kissova, Miroslava, Crespan, Emmanuele, Maga, Giovanni, and Schenone, Silvia
- Subjects
- *
PYRIMIDINES , *PROTEIN-tyrosine kinase inhibitors , *GLIOBLASTOMA multiforme treatment , *CHEMICAL derivatives , *CLINICAL trials , *IN vitro studies - Abstract
In the last few years, several pyrrolo-pyrimidine derivatives have been either approved by the US FDA and in other countries for the treatment of different diseases or are currently in phase I/II clinical trials. Herein we present the synthesis and the characterization of a novel series of pyrrolo[2,3- d ]pyrimidines, compounds 8a-j , and their activity against Glioblastoma multiforme (GBM). Docking studies and MM-GBSA analysis revealed the ability of such compounds to efficiently interact with the ATP binding site of Src. Enzymatic assays against a mini-panel of kinases (Src, Fyn, EGFR, Kit, Flt3, Abl, AblT315I) have been performed, showing an unexpected selectivity of our pyrrolo[2,3- d ]pyrimidines for Src. Finally, the derivatives were tested for their antiproliferative potency on U87 GBM cell line. Compound 8h showed a considerable cytotoxicity effect against U87 cell line with an IC 50 value of 7.1 μM. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
173. Antimicrobial Evaluation of New Pyrazoles, Indazoles and Pyrazolines Prepared in Continuous Flow Mode.
- Author
-
Burke, Adam, Di Filippo, Mara, Spiccio, Silvia, Schito, Anna Maria, Caviglia, Debora, Brullo, Chiara, and Baumann, Marcus
- Subjects
- *
INDAZOLES , *PYRAZOLES , *CHEMICAL libraries , *ANTIBIOTICS , *STAPHYLOCOCCUS aureus , *LEAD compounds , *FLOW chemistry - Abstract
Multi-drug resistant bacterial strains (MDR) have become an increasing challenge to our health system, resulting in multiple classical antibiotics being clinically inactive today. As the de-novo development of effective antibiotics is a very costly and time-consuming process, alternative strategies such as the screening of natural and synthetic compound libraries is a simple approach towards finding new lead compounds. We thus report on the antimicrobial evaluation of a small collection of fourteen drug-like compounds featuring indazoles, pyrazoles and pyrazolines as key heterocyclic moieties whose synthesis was achieved in continuous flow mode. It was found that several compounds possessed significant antibacterial potency against clinical and MDR strains of the Staphylococcus and Enterococcus genera, with the lead compound (9) reaching MIC values of 4 µg/mL on those species. In addition, time killing experiments performed on compound 9 on Staphylococcus aureus MDR strains highlight its activity as bacteriostatic. Additional evaluations regarding the physiochemical and pharmacokinetic properties of the most active compounds are reported and showcased, promising drug-likeness, which warrants further explorations of the newly identified antimicrobial lead compound. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
174. Pyrazole-Enriched Cationic Nanoparticles Induced Early- and Late-Stage Apoptosis in Neuroblastoma Cells at Sub-Micromolar Concentrations.
- Author
-
Zuccari, Guendalina, Zorzoli, Alessia, Marimpietri, Danilo, Brullo, Chiara, and Alfei, Silvana
- Subjects
- *
CELL death , *CLINICAL trials , *NEUROBLASTOMA , *NEURONS , *APOPTOSIS , *CANCER cells , *CHEMORECEPTORS , *CELL membranes - Abstract
Neuroblastoma (NB) is a severe form of tumor occurring mainly in young children and originating from nerve cells found in the abdomen or next to the spine. NB needs more effective and safer treatments, as the chance of survival against the aggressive form of this disease are very small. Moreover, when current treatments are successful, they are often responsible for unpleasant health problems which compromise the future and life of surviving children. As reported, cationic macromolecules have previously been found to be active against bacteria as membrane disruptors by interacting with the negative constituents of the surface of cancer cells, analogously inducing depolarization and permeabilization, provoking lethal damage to the cytoplasmic membrane, and cause loss of cytoplasmic content and consequently, cell death. Here, aiming to develop new curative options for counteracting NB cells, pyrazole-loaded cationic nanoparticles (NPs) (BBB4-G4K and CB1H-P7 NPs), recently reported as antibacterial agents, were assayed against IMR 32 and SHSY 5Y NB cell lines. Particularly, while BBB4-G4K NPs demonstrated low cytotoxicity against both NB cell lines, CB1H-P7 NPs were remarkably cytotoxic against both IMR 32 and SHSY 5Y cells (IC50 = 0.43–0.54 µM), causing both early-stage (66–85%) and late-stage apoptosis (52–65%). Interestingly, in the nano-formulation of CB1H using P7 NPs, the anticancer effects of CB1H and P7 were increased by 54–57 and 2.5–4-times, respectively against IMR 32 cells, and by 53–61 and 1.3–2 times against SHSY 5Y cells. Additionally, based on the IC50 values, CB1H-P7 was also 1-12-fold more potent than fenretinide, an experimental retinoid derivative in a phase III clinical trial, with remarkable antineoplastic and chemopreventive properties. Collectively, due to these results and their good selectivity for cancer cells (selectivity indices = 2.8–3.3), CB1H-P7 NPs represent an excellent template material for developing new treatment options against NB. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
175. Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.
- Author
-
Schepers, Melissa, Paes, Dean, Tiane, Assia, Rombaut, Ben, Piccart, Elisabeth, van Veggel, Lieve, Gervois, Pascal, Wolfs, Esther, Lambrichts, Ivo, Brullo, Chiara, Bruno, Olga, Fedele, Ernesto, Ricciarelli, Roberta, ffrench-Constant, Charles, Bechler, Marie E., van Schaik, Pauline, Baron, Wia, Lefevere, Evy, Wasner, Kobi, and Grünewald, Anne
- Subjects
- *
MYELIN sheath diseases , *MULTIPLE sclerosis , *MYELIN oligodendrocyte glycoprotein , *CYCLIC adenylic acid , *CENTRAL nervous system diseases , *MYELIN , *VISUAL evoked potentials - Abstract
[Display omitted] • Selective inhibition of PDE4 gene products and isoforms provides new opportunities in the PDE4 inhibition field, especially for MS. • Selective PDE4B inhibition suppresses inflammatory responses by phagocytes. • PDE4D, but not PDE4B inhibition promotes oligodendrocyte differentiation and thus enhances remyelination. • The therapeutic dose of the applied PDE4B and PDE4D inhibitors does not induce emetic side effects. • PDE4D isoform fingerprints in human area postrema neurons and MS lesions reveal novel targets to stimulate remyelination while avoiding emesis. Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by focal inflammatory lesions and prominent demyelination. Even though the currently available therapies are effective in treating the initial stages of disease, they are unable to halt or reverse disease progression into the chronic progressive stage. Thus far, no repair-inducing treatments are available for progressive MS patients. Hence, there is an urgent need for the development of new therapeutic strategies either targeting the destructive immunological demyelination or boosting endogenous repair mechanisms. Using in vitro , ex vivo, and in vivo models, we demonstrate that selective inhibition of phosphodiesterase 4 (PDE4), a family of enzymes that hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP), reduces inflammation and promotes myelin repair. More specifically, we segregated the myelination-promoting and anti-inflammatory effects into a PDE4D- and PDE4B-dependent process respectively. We show that inhibition of PDE4D boosts oligodendrocyte progenitor cells (OPC) differentiation and enhances (re)myelination of both murine OPCs and human iPSC-derived OPCs. In addition, PDE4D inhibition promotes in vivo remyelination in the cuprizone model, which is accompanied by improved spatial memory and reduced visual evoked potential latency times. We further identified that PDE4B-specific inhibition exerts anti-inflammatory effects since it lowers in vitro monocytic nitric oxide (NO) production and improves in vivo neurological scores during the early phase of experimental autoimmune encephalomyelitis (EAE). In contrast to the pan PDE4 inhibitor roflumilast, the therapeutic dose of both the PDE4B-specific inhibitor A33 and the PDE4D-specific inhibitor Gebr32a did not trigger emesis-like side effects in rodents. Finally, we report distinct PDE4D isoform expression patterns in human area postrema neurons and human oligodendroglia lineage cells. Using the CRISPR-Cas9 system, we confirmed that pde4d1/2 and pde4d6 are the key targets to induce OPC differentiation. Collectively, these data demonstrate that gene specific PDE4 inhibitors have potential as novel therapeutic agents for targeting the distinct disease processes of MS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
176. 2-Aryl-3-phenylamino-4,5-dihydro-2H-benz[g]indazoles with Analgesic Activity.
- Author
-
Schenone, Silvia, Bruno, Olga, Ranise, Angelo, Brullo, Chiara, Bondavalli, Francesco, Filippelli, Walter, Mazzeo, Filomena, Capuano, Annalisa, and Falcone, Giuseppe
- Published
- 2004
- Full Text
- View/download PDF
177. Hydrogel Formulations of Antibacterial Pyrazoles Using a Synthesized Polystyrene-Based Cationic Resin as a Gelling Agent.
- Author
-
Alfei, Silvana, Zuccari, Guendalina, Russo, Eleonora, Villa, Carla, and Brullo, Chiara
- Subjects
- *
GELATION , *PYRAZOLES , *ATTENUATED total reflectance , *HYDROGELS , *CATIONIC surfactants , *STAPHYLOCOCCAL diseases , *CHEMICAL structure - Abstract
Here, to develop new topical antibacterial formulations to treat staphylococcal infections, two pyrazoles (3c and 4b) previously reported as antibacterial agents, especially against staphylococci, were formulated as hydrogels (R1-HG-3c and R1HG-4b) using a cationic polystyrene-based resin (R1) and here synthetized and characterized as gelling agents. Thanks to the high hydrophilicity, high-level porosity, and excellent swelling capabilities of R1, R1HG-3c and R1HG-4b were achieved with an equilibrium degree of swelling (EDS) of 765% (R1HG-3c) and 675% (R1HG-4b) and equilibrium water content (EWC) of 88% and 87%, respectively. The chemical structure of soaked and dried gels was investigated by PCA-assisted attenuated total reflectance (ATR) Fourier transform infrared (FTIR) spectroscopy, while their morphology was investigated by optical microscopy. Weight loss studies were carried out with R1HG-3c and R1HG-4b to investigate their water release profiles and the related kinetics, while their stability was evaluated over time both by monitoring their inversion properties to detect possible impairments of the 3D network and by PCA-assisted ATR-FTIR spectroscopy to detect possible structural changes. The flow and dynamic rheological characterization of the gels was assessed by determining their viscosity vs. shear rate, applying the Cross rheological equation to achieve the curves of shear stress vs. shear rate, and carrying out amplitude and frequency sweep experiments. Finally, their content in NH3+ groups was determined by potentiometric titrations. Due to their favorable physicochemical characteristic and the antibacterial effects of 3c and 4b possibly improved by the cationic R1, the pyrazole-enriched gels reported here could represent new weapons to treat severe skin and wound infections sustained by MDR bacteria of staphylococcal species. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
178. Novel tetrasubstituted 5-Arylamino pyrazoles able to interfere with angiogenesis and Ca2+ mobilization.
- Author
-
Lusardi, Matteo, Belvedere, Raffaella, Petrella, Antonello, Iervasi, Erika, Ponassi, Marco, Brullo, Chiara, and Spallarossa, Andrea
- Subjects
- *
CANCER cell migration , *ENDOTHELIAL cells , *STRUCTURE-activity relationships , *LEAD compounds , *CARRIER proteins - Abstract
In the last years, 5-pyrazolyl ureas and 5-aminopyrazoles have been investigated for their antiangiogenetic properties and their potential interaction with the ubiquitous Ca2+ binding protein Calreticulin. Based on the structure of the active compounds I and GeGe-3 , novel 5-arylamino pyrazoles 2 and 3 were synthesized through a stepwise procedure. In MTT assays, all the new derivatives proved to be non-cytotoxic against eight different tumor cell lines, normal fibroblasts, and endothelial cells. Furthermore, selected derivatives showed relevant antiangiogenetic properties, resulting more effective than reference molecules I and GeGe-3 in inhibiting HUVEC endothelial tube formation. 5-Arylamino pyrazoles 2a and 2d were identified as the most interesting compounds and significantly prevented tube formation of tumor secretome-stimulated HUVEC. Furthermore, the two compounds inhibited HUVEC migration in wound healing assay and altered cell invasion capability. Additionally, 2a and 2d strongly affected Ca2+ mobilization and cytoskeletal organization of HUVEC cells, being as active as the reference compound GeGe-3. Differently from previous studies, molecular docking simulations suggested a poor affinity of 2a towards Calreticulin, one of the interacting partners of the lead compound GeGe-3. Collectively, this new amino-pyrazole library further extends the structure-activity relationships of the previously prepared derivatives and confirmed the biological attractiveness of this chemical scaffold as antiangiogenetic agents. [Display omitted] • To extend SARs of antiangiogenic compounds I and GeGe- 3, aminopyrazole derivatives 2 and 3 were designed and synthesized. • Selected compounds inhibited the endothelial cells tube formation without showing any cytotoxicity. • Pyrazoles 2a and 2d showed antiangiogenetic properties on unstimulated and tumor secretome-stimulated HUVEC cells. • 2a and 2d interfered with Calcium mobilization and F-actin organization in HUVEC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
179. Nanotechnology for Pediatric Retinoblastoma Therapy.
- Author
-
Russo, Eleonora, Spallarossa, Andrea, Tasso, Bruno, Villa, Carla, and Brullo, Chiara
- Subjects
- *
DRUG delivery systems , *PEDIATRIC therapy , *NANOMEDICINE , *CHILDHOOD cancer , *HIGH-income countries , *NANOTECHNOLOGY , *MIDDLE-income countries - Abstract
Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocols are applied. In more advanced forms of the disease, surgical removal of the entire globe and its intraocular contents (enucleation) is, unfortunately, necessary, whereas in other cases, conventional chemotherapy is normally used. To overcome the side-effects and reduced efficacy of traditional chemotherapic drugs, nanodelivery systems that ensure a sustained drug release and manage to reach the target site have more recently been developed. This review takes into account the current use and advances of nanomedicine in the treatment of retinoblastoma and discusses nanoparticulate formulations that contain conventional drugs and natural products. In addition, future developments in retinoblastoma treatment are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
180. The Development of FAK Inhibitors: A Five-Year Update.
- Author
-
Spallarossa, Andrea, Tasso, Bruno, Russo, Eleonora, Villa, Carla, and Brullo, Chiara
- Subjects
- *
FOCAL adhesion kinase , *PHARMACEUTICAL chemistry , *ANTINEOPLASTIC agents , *METASTASIS - Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase over-expressed in different solid cancers. In recent years, FAK has been recognized as a new target for the development of antitumor agents, useful to contrast tumor development and metastasis formation. To date, studies on the role of FAK and FAK inhibitors are of great interest for both pharmaceutical companies and academia. This review is focused on compounds able to block FAK with different potencies and with different mechanisms of action, that have appeared in the literature since 2017. Furthermore, new emerging PROTAC molecules have appeared in the literature. This summary could improve knowledge of new FAK inhibitors and provide information for future investigations, in particular, from a medicinal chemistry point of view. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
181. Synthesis and Characterization of Pyrazole-Enriched Cationic Nanoparticles as New Promising Antibacterial Agent by Mutual Cooperation.
- Author
-
Alfei, Silvana, Zuccari, Guendalina, Caviglia, Debora, and Brullo, Chiara
- Abstract
A pyrazole derivative (CB1) was previously evaluated in vivo for various pharmacological activities (with the exception of antimicrobial effects), using DMSO as the administrative medium, mainly due to its water insolubility. Considering the global necessity for new antimicrobial agents, CB1 attracted our attention as a candidate to meet this need, mainly because the secondary amine group in its structure would make it possible to obtain its hydrochloride salt (CB1H), thus effortlessly solving its water-solubility drawbacks. In preliminary microbiologic investigations on Gram-negative and Gram-positive bacteria, CB1H displayed weak antibacterial effects on MDR isolates of Gram-positive species, nonetheless better than those displayed by the commonly-used available antibiotics. Therefore, aiming at improving such activity and extending the antibacterial spectrum of CB1H to Gram-negative pathogens, in this first work CB1 was strategically formulated in nanoparticles using a cationic copolymer (P7) previously developed by us, possessing potent broad-spectrum bactericidal activity. Using the nanoprecipitation method, CB1H-loaded polymer nanoparticles (CB1H-P7 NPs) were obtained, which were analyzed by attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy to confirm the successful loading. Additionally, CB1H-P7 NPs were fully characterized in terms of morphology, size, polydispersity indices, surface charge, DL%, and EE%, as well as release and potentiometric profiles. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
182. Novel 5-aminopyrazoles endowed with anti-angiogenetic properties: Design, synthesis and biological evaluation.
- Author
-
Lusardi, Matteo, Wehrle-Haller, Bernhard, Sidibe, Adama, Ponassi, Marco, Iervasi, Erika, Rosano, Camillo, Brullo, Chiara, and Spallarossa, Andrea
- Subjects
- *
BIOSYNTHESIS , *CELL migration , *UMBILICAL veins , *STRUCTURE-activity relationships , *WOUND healing - Abstract
The promising anti-angiogenetic properties of previously synthesized pyrazolyl ureas provided the rationale for the synthesis of novel 5-aminopyrazoles 2–5 , differently decorated on the pyrazole nucleus. All the derivatives were tested by MTT assays and proved to be non-cytotoxic against eight different tumor cell lines and normal fibroblasts. An EdU proliferation assay was carried out on human foreskin fibroblasts and VEGF stimulated human umbilical vein endothelial cells which confirmed the absence of cytotoxicity of the compounds on human cells up to 20 μM concentration. To evaluate the influence of the newly synthesized pyrazoles on MAPK and PI3K signaling pathways, the phosphorylation of ERK1/2 and Akt was analyzed by Western blots from HFF and HUVEC cell lysates stimulated with growth factors in the presence or absence of the compounds. Pyrazoles 3b and 3c showed a significant inhibition of Akt phosphorylation in both tested cell lines with lower phosphorylation levels than the reference compound GeGe-3 in HUVEC. Furthermore, derivatives 2 and 3 appeared to strongly affect the migration of HFF cells in a wound healing assay, confirming their potential ability to interfere with the angiogenesis process. The new pyrazole library extends the structure-activity relationships of the previously isolated compounds and highlights the attractiveness of this chemical class for pathological cell migration and angiogenesis. [Display omitted] • Aminopyrazole derivatives 2–5 were designed and synthesized as novel antiangiogenetic agents. • The compounds did not show any cytotoxicity on tumor and normal cell lines in MTT and EdU proliferation assays. • Pyrazoles 3b and 3c significantly inhibited the Akt phosphorylation in HFF and HUVEC cells equaling reference drugs. • Derivatives 2 and 3 were able to strongly interfere with HFF migration in wound healing assay. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
183. Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis
- Author
-
Melissa Schepers, Dean Paes, Assia Tiane, Ben Rombaut, Elisabeth Piccart, Lieve van Veggel, Pascal Gervois, Esther Wolfs, Ivo Lambrichts, Chiara Brullo, Olga Bruno, Ernesto Fedele, Roberta Ricciarelli, Charles ffrench-Constant, Marie E. Bechler, Pauline van Schaik, Wia Baron, Evy Lefevere, Kobi Wasner, Anne Grünewald, Catherine Verfaillie, Paulien Baeten, Bieke Broux, Paul Wieringa, Niels Hellings, Jos Prickaerts, Tim Vanmierlo, Grunewald, Anne/0000-0002-4179-2994, SCHEPERS, Melissa, PAES, Dean, TIANE, Assia, ROMBAUT, Ben, PICCART, Elisabeth, VAN VEGGEL, Lieve, GERVOIS, Pascal, Brullo, Chiara, Bruno, Olga, Fedele, Ernesto, Ricciarelli, Roberta, Ffrench-Constant, Charles, Bechler, Marie E., Schaik, Pauline van, WOLFS, Esther, LAMBRICHTS, Ivo, Baron, Wia, LEFEVERE, Evy, Wasner, Kobi, Gruenewald, Anne, Verfaillie, Catherine, Wieringa, Paul, Prickaerts, Jos, BROUX, Bieke, BAETEN, Paulien, HELLINGS, Niels, VANMIERLO, Tim, RS: MHeNs - R3 - Neuroscience, Basic Neuroscience 2, Basic Neuroscience 1, CTR, RS: MERLN - Complex Tissue Regeneration (CTR), and Psychiatrie & Neuropsychologie
- Subjects
Multiple sclerosis ,Behavioral Neuroscience ,Neuroinflammation ,Remyelination ,Endocrine and Autonomic Systems ,Phosphodiesterases ,Immunology ,Biochemistry, biophysics & molecular biology [F05] [Life sciences] ,Biochimie, biophysique & biologie moléculaire [F05] [Sciences du vivant] - Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by focal inflammatory lesions and prominent demyelination. Even though the currently available therapies are effective in treating the initial stages of disease, they are unable to halt or reverse disease progression into the chronic progressive stage. Thus far, no repair-inducing treatments are available for progressive MS patients. Hence, there is an urgent need for the development of new therapeutic strategies either targeting the destructive immunological demyelination or boosting endogenous repair mechanisms. Using in vitro, ex vivo, and in vivo models, we demonstrate that selective inhibition of phosphodiesterase 4 (PDE4), a family of enzymes that hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP), reduces inflammation and promotes myelin repair. More specifically, we segregated the myelination-promoting and anti-inflammatory effects into a PDE4Dand PDE4B-dependent process respectively. We show that inhibition of PDE4D boosts oligodendrocyte progenitor cells (OPC) differentiation and enhances (re)myelination of both murine OPCs and human iPSC-derived OPCs. In addition, PDE4D inhibition promotes in vivo remyelination in the cuprizone model, which is accompanied by improved spatial memory and reduced visual evoked potential latency times. We further identified that PDE4B-specific inhibition exerts anti-inflammatory effects since it lowers in vitro monocytic nitric oxide (NO) production and improves in vivo neurological scores during the early phase of experimental autoimmune encephalomyelitis (EAE). In contrast to the pan PDE4 inhibitor roflumilast, the therapeutic dose of both the PDE4B-specific inhibitor A33 and the PDE4D-specific inhibitor Gebr32a did not trigger emesis-like side effects in rodents. Finally, we report distinct PDE4D isoform expression patterns in human area postrema neurons and human oligodendroglia lineage cells. Using the CRISPR-Cas9 system, we confirmed that pde4d1/2 and pde4d6 are the key targets to induce OPC differentiation. Collectively, these data demonstrate that gene specific PDE4 inhibitors have potential as novel therapeutic agents for targeting the distinct disease processes of MS. This work has been supported by FWO (12G0817N, 1S57521N, G041421N, and 12G0817N), Fondation Charctot Stichting (ID2020- 0019), Nationale Belgische Multiple Sclerose Liga (Charco18VT), MS Liga Vlaanderen and Stichting MS Research (18-1016 MS). MS, EP, JP and TV have a proprietary interest in selective PDE4D inhibitors for the treatment of demyelinating disorders and neurodegenerative disorders. JP has a proprietary interest in the PDE4 inhibitor roflumilast for the treatment of cognitive impairment as well as PDE4D inhibitors for the treatment of Alzheimer’s disease. We thank Prof. Dr. O.N. Viacheslav (University Medical Center Hamburg-Eppendorf, German Center for Cardiovascular Research) and Prof. Dr. M. Conti (University of California), for providing the PDE4B KO animals. Furthermore, we thank Rewind Therapeutics for providing the visual evoked potential equipment.
- Published
- 2023
184. Insight into GEBR-32a: Chiral Resolution, Absolute Configuration and Enantiopreference in PDE4D Inhibition
- Author
-
Federica Rapetti, Francesca Vasile, Katia Russo, Daniela Rossi, Chiara Brullo, Paola Storici, Archimede Torretta, Simona Collina, Marta S. Semrau, Stefano Donini, Emilio Parisini, Luca Pignataro, Valeria Cavalloro, Olga Bruno, Cavalloro, Valeria, Russo, Katia, Vasile, Francesca, Pignataro, Luca, Torretta, Archimede, Donini, Stefano, Semrau, Marta S, Storici, Paola, Rossi, Daniela, Rapetti, Federica, Brullo, Chiara, Parisini, Emilio, Bruno, Olga, and Collina, Simona
- Subjects
Gene isoform ,Stereochemistry ,PDE4 inhibition ,Pharmaceutical Science ,Article ,Analytical Chemistry ,lcsh:QD241-441 ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,lcsh:Organic chemistry ,NMR absolute configuration assignment ,Drug Discovery ,medicine ,Humans ,Cyclic adenosine monophosphate ,Physical and Theoretical Chemistry ,Nuclear Magnetic Resonance, Biomolecular ,HPLC chiral resolution ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Chemistry ,Organic Chemistry ,Absolute configuration ,Phosphodiesterase ,Chiral resolution ,Cyclic Nucleotide Phosphodiesterases, Type 4 ,Enzyme ,Mechanism of action ,Chemistry (miscellaneous) ,Molecular Medicine ,Phosphodiesterase 4 Inhibitors ,Enantiomer ,medicine.symptom ,030217 neurology & neurosurgery - Abstract
Alzheimer&rsquo, s disease is the most common type of dementia, affecting millions of people worldwide. One of its main consequences is memory loss, which is related to downstream effectors of cyclic adenosine monophosphate (cAMP). A well-established strategy to avoid cAMP degradation is the inhibition of phosphodiesterase (PDE). In recent years, GEBR-32a has been shown to possess selective inhibitory properties against PDE type 4 family members, resulting in an improvement in spatial memory processes without the typical side effects that are usually correlated with this mechanism of action. In this work, we performed the HPLC chiral resolution and absolute configuration assignment of GEBR-32a. We developed an efficient analytical and semipreparative chromatographic method exploiting an amylose-based stationary phase, we studied the chiroptical properties of both enantiomers and we assigned their absolute configuration by 1H-NMR (nuclear magnetic resonance). Lastly, we measured the IC50 values of both enantiomers against both the PDE4D catalytic domain and the long PDE4D3 isoform. Results strongly support the notion that GEBR-32a inhibits the PDE4D enzyme by interacting with both the catalytic pocket and the regulatory domains.
- Published
- 2020
- Full Text
- View/download PDF
185. Synthesis, functional proteomics and biological evaluation of new 5-pyrazolyl ureas as potential anti-angiogenic compounds.
- Author
-
Morretta, Elva, Sidibè, Adama, Spallarossa, Andrea, Petrella, Antonello, Meta, Elda, Bruno, Olga, Monti, Maria Chiara, and Brullo, Chiara
- Subjects
- *
UREA derivatives , *CELLULAR signal transduction , *PROTEOMICS , *UREA , *MOLECULAR docking , *PROTEIN-ligand interactions - Abstract
Based on biological results of previous synthesized pyrazolyl ureas able to interfere with angiogenesis process, we planned and synthesized the new benzyl-urea derivatives 2 – 4 ; some of them showed an interesting anti-proliferative profile and particularly 4e potently inhibited HUVEC proliferation. To shed light on the mechanism of action of 4e , its interactome has been deeply inspected to identify the most prominent protein partners, mainly taking into account kinome and phosphatome, through drug affinity responsive target stability experiments, followed by targeted limited proteolysis analysis. From these studies, PP1γ emerged as the most reliable 4 e potential target in HUVEC. Molecular docking simulations on PP1γ were carried out to predict 4e binding mode. To assess its potential anti-angiogenic effect, 4e was tested in vitro to verify interference on kinase and phosphate activities. Overall, our results evidenced for 4e an interesting anti-angiogenic action, probably due to its action at intracellular level on PP1γ signalling pathways. [Display omitted] • New derivatives 2–4 were designed and synthesized, showing good proliferation inhibition of cancer and HUVEC cells. • The interactome of 4e was investigated by DARTS and t-LiP experiments to identify its target(s). • PP1γ emerged as possible target protein involved in intracellular mechanism of action of 4e in HUVEC cells. • Molecular docking simulation on PP1γ was performed to verify a possible interaction. • Compound 4e showed potential anti-angiogenic action through PP1γ signalling pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
186. The Development of BTK Inhibitors: A Five-Year Update.
- Author
-
Tasso, Bruno, Spallarossa, Andrea, Russo, Eleonora, and Brullo, Chiara
- Subjects
- *
BRUTON tyrosine kinase , *AUTOIMMUNE diseases - Abstract
Bruton's tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders. To date, five compounds, able to block BTK in an irreversible manner, have been launched in the market, whereas many reversible BTK inhibitors (BTKIs), with reduced side effects that are more useful for long-term administration in autoimmune disorders, are under clinical investigation. Despite the presence in the literature of many articles and reviews, studies on BTK function and BTKIs are of great interest for pharmaceutical companies as well as academia. This review is focused on compounds that have appeared in the literature from 2017 that are able to block BTK in an irreversible or reversible manner; also, new promising tunable irreversible inhibitors, as well as PROTAC molecules, have been reported. This summary could improve the knowledge of the chemical diversity of BTKIs and provide information for future studies, particularly from the medicinal chemistry point of view. Data reported here are collected from different databases (Scifinder, Web of Science, Scopus, Google Scholar, and Pubmed) using "BTK" and "BTK inhibitors" as keywords. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
187. The Pyrazolyl-Urea Gege3 Inhibits the Activity of ANXA1 in the Angiogenesis Induced by the Pancreatic Cancer Derived EVs.
- Author
-
Belvedere, Raffaella, Morretta, Elva, Novizio, Nunzia, Morello, Silvana, Bruno, Olga, Brullo, Chiara, and Petrella, Antonello
- Subjects
- *
PANCREATIC cancer , *NEOVASCULARIZATION , *CELL motility , *EXTRACELLULAR vesicles , *CELL membranes - Abstract
The pyrazolyl-urea Gege3 molecule has shown interesting antiangiogenic effects in the tumor contest. Here, we have studied the role of this compound as interfering with endothelial cells activation in response to the paracrine effects of annexin A1 (ANXA1), known to be involved in promoting tumor progression. ANXA1 has been analyzed in the extracellular environment once secreted through microvesicles (EVs) by pancreatic cancer (PC) cells. Particularly, Gege3 has been able to notably prevent the effects of Ac2-26, the ANXA1 mimetic peptide, and of PC-derived EVs on endothelial cells motility, angiogenesis, and calcium release. Furthermore, this compound also inhibited the translocation of ANXA1 to the plasma membrane, otherwise induced by the same ANXA1-dependent extracellular stimuli. Moreover, these effects have been mediated by the indirect inhibition of protein kinase Cα (PKCα), which generally promotes the phosphorylation of ANXA1 on serine 27. Indeed, by the subtraction of intracellular calcium levels, the pathway triggered by PKCα underwent a strong inhibition leading to the following impediment to the ANXA1 localization at the plasma membrane, as revealed by confocal and cytofluorimetry analysis. Thus, Gege3 appeared an attractive molecule able to prevent the paracrine effects of PC cells deriving ANXA1 in the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
188. 2-Aryl-3-phenylamino-4,5-dihydro-2h-benz[g]indazoles with analgesic activity
- Author
-
Schenone, Silvia, Bruno, Olga, Ranise, Angelo, Brullo, Chiara, Bondavalli, Francesco, Filippelli, Walter, Mazzeo, Filomena, Capuano, Annalisa, and Falcone, Giuseppe
- Subjects
- *
LOCAL anesthetics , *ANALGESICS , *CENTRAL nervous system depressants , *MYOCARDIAL depressants , *CHEMICAL processes - Abstract
A series of 2-aryl-3-phenylamino-4,5-dihydro-2H-benz[g]indazoles was synthesized and tested for antiarrhythmic, local anaesthetic and analgesic activity. The title compounds showed a good antinociceptive activity. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
189. New Series of Pyrazoles and Imidazo-Pyrazoles Targeting Different Cancer and Inflammation Pathways.
- Author
-
Signorello, Maria Grazia, Rapetti, Federica, Meta, Elda, Sidibè, Adama, Bruno, Olga, and Brullo, Chiara
- Subjects
- *
PYRAZOLES , *NEOVASCULARIZATION inhibitors , *UMBILICAL veins , *BLOOD platelet aggregation , *INFLAMMATION , *PHOSPHORYLATION - Abstract
(1) Background: different previously synthesized pyrazoles and imidazo-pyrazoles showed interesting anti-angiogenic action, being able to interfere with ERK1/2, AKT and p38MAPK phosphorylation in different manners and with different potency; (2) Methods: here, a new small compound library, endowed with the same differently decorated chemical scaffolds, has been synthetized to obtain new agents able to inhibit different pathways involved in inflammation, cancer and human platelet aggregation. (3) Results: most of the new synthesized derivatives resulted able to block ROS production, platelet aggregation and p38MAPK phosphorylation both in platelets and Human Umbilical Vein Endothelial cells (HUVEC). This paves the way for the development of new agents with anti-angiogenic activity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
190. Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics.
- Author
-
Morretta, Elva, Belvedere, Raffaella, Petrella, Antonello, Spallarossa, Andrea, Rapetti, Federica, Bruno, Olga, Brullo, Chiara, and Monti, Maria Chiara
- Subjects
- *
PROTEOMICS , *MOLECULAR docking , *CALRETICULIN , *MASS spectrometry , *PROTEIN-ligand interactions , *FOCAL adhesion kinase - Abstract
[Display omitted] • A 5-pyrazolyl-urea compound (GeGe-3) interactome has been studied by proteomics. • Calreticulin has been validated as GeGe-3 target by immunoblotting and docking. • GeGe-3 lowers calcium mobilization, cytoskeleton organization and FAK expression. In recent years, 5-pyrazolyl-ureas have mostly been known for their attractive poly-pharmacological outline and, in particular, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl) ureido)-1 H -pyrazole-4-carboxylate (named GeGe-3) has emerged as a capable anti-angiogenic compound. This paper examines its interactome by functional proteomics using a label-free mass spectrometry based platform, coupling Drug Affinity Responsive Target Stability and targeted Limited Proteolysis-Multiple Reaction Monitoring. Calreticulin has been recognized as the GeGe-3 principal target and this evidence has been supported by immunoblotting and in silico molecular docking. Furthermore, cell studies have shown that GeGe-3 lowers cell calcium mobilization, cytoskeleton organization and focal adhesion kinase expression, thus linking its biological potential to calreticulin binding and, ultimately, shedding light on the reasonable action mechanism of this molecule as an anti-angiogenic factor. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
191. Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective.
- Author
-
Russo, Eleonora, Spallarossa, Andrea, Tasso, Bruno, Villa, Carla, and Brullo, Chiara
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *DRUG delivery systems , *BIOAVAILABILITY , *LIPOSOMES , *DRUG side effects , *CANCER treatment , *NANOTECHNOLOGY , *BLOOD circulation - Abstract
Nanotechnology is an important application in modern cancer therapy. In comparison with conventional drug formulations, nanoparticles ensure better penetration into the tumor mass by exploiting the enhanced permeability and retention effect, longer blood circulation times by a reduced renal excretion and a decrease in side effects and drug accumulation in healthy tissues. The most significant classes of nanoparticles (i.e., liposomes, inorganic and organic nanoparticles) are here discussed with a particular focus on their use as delivery systems for small molecule tyrosine kinase inhibitors (TKIs). A number of these new compounds (e.g., Imatinib, Dasatinib, Ponatinib) have been approved as first-line therapy in different cancer types but their clinical use is limited by poor solubility and oral bioavailability. Consequently, new nanoparticle systems are necessary to ameliorate formulations and reduce toxicity. In this review, some of the most important TKIs are reported, focusing on ongoing clinical studies, and the recent drug delivery systems for these molecules are investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
192. Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds
- Author
-
Luca Mollica, Egidio Aiolfi, Olga Bruno, Tommaso Prosdocimi, Silvana Alfei, Marta S. Semrau, Paola Storici, Andrea Cavalli, Stefano Donini, Emilio Parisini, Chiara Brullo, A.P. Lucarelli, Prosdocimi, Tommaso, Mollica, Luca, Donini, Stefano, Semrau, Marta S., Lucarelli, Anna Paola, Aiolfi, Egidio, Cavalli, Andrea, Storici, Paola, Alfei, Silvana, Brullo, Chiara, Bruno, Olga, and Parisini, Emilio
- Subjects
0301 basic medicine ,Gene isoform ,Stereochemistry ,Context (language use) ,Ligand ,Molecular Dynamics Simulation ,Crystallography, X-Ray ,Ligands ,Biochemistry ,03 medical and health sciences ,Molecular dynamics ,Structure-Activity Relationship ,0302 clinical medicine ,Memory ,Catalytic Domain ,Hydrolase ,Structure–activity relationship ,Animals ,Humans ,chemistry.chemical_classification ,Animal ,Phosphodiesterase ,Cyclic Nucleotide Phosphodiesterases, Type 4 ,030104 developmental biology ,Enzyme ,chemistry ,Phosphodiesterase 4 Inhibitor ,Phosphodiesterase 4 Inhibitors ,Rolipram ,030217 neurology & neurosurgery ,Human - Abstract
Selected members of the large rolipram-related GEBR family of type 4 phosphodiesterase (PDE4) inhibitors have been shown to facilitate long-term potentiation and to improve memory functions without causing emetic-like behavior in rodents. Despite their micromolar-range binding affinities and their promising pharmacological and toxicological profiles, few if any structure-activity relationship studies have been performed to elucidate the molecular bases of their action. Here, we report the crystal structure of a number of GEBR library compounds in complex with the catalytic domain of PDE4D as well as their inhibitory profiles for both the long PDE4D3 isoform and the catalytic domain alone. Furthermore, we assessed the stability of the observed ligand conformations in the context of the intact enzyme using molecular dynamics simulations. The longer and more flexible ligands appear to be capable of forming contacts with the regulatory portion of the enzyme, thus possibly allowing some degree of selectivity between the different PDE4 isoforms.
- Published
- 2018
193. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7.
- Author
-
Gütschow, Michael, Vanden Eynde, Jean Jacques, Jampilek, Josef, Kang, CongBao, Mangoni, Arduino A., Fossa, Paola, Karaman, Rafik, Trabocchi, Andrea, Scott, Peter J. H., Reynisson, Jóhannes, Rapposelli, Simona, Galdiero, Stefania, Winum, Jean-Yves, Brullo, Chiara, Prokai-Tatrai, Katalin, Sharma, Arun K., Schapira, Matthieu, Azuma, Yasu-Taka, Cerchia, Laura, and Spetea, Mariana
- Subjects
- *
AMYLOID beta-protein , *PHARMACEUTICAL chemistry , *PROTEASOMES , *PACLITAXEL , *DRUGS , *MATERIALS science , *COVID-19 , *DRUG side effects - Abstract
New InhA Inhibitors Provided by Fragment-Based Drug Design Highlighted by Josef Jampilek and CongBao Kang Fragment-based drug design (FBDD), despite its youth, has provided marketed drugs and others in clinical trials. However, a recent report [[21]] suggests that resistance is inevitable for KRAS SP G12C sp inhibitors since the cancer cells develop a heterogeneous response to the inhibitors and bypass inhibition by producing new active KRAS SP G12C sp that does not bind the inhibitor, indicating that the challenge to develop efficient inhibitors and achieve complete responses in the clinic continues. An NMR Drug Screening Approach in Human Cells as a New Tool for Drug Potency Early Assess... Highlighted by Tiziano Tuccinardi and Iola F. Duarte A classical drug development workflow usually starts by screening the activity of multiple ligands against the selected target. Among other potential compounds, the c-Jun N-terminal kinase inhibitor SU3327 (halicin) was identified as a potent I E. coli i growth inhibitor. Glucuronide Prodrug, PEGylation, Albumin Binder, Self-Immolative Linker, and a Potent Tox... Highlighted by Jarkko Rautio and Diego Muñoz-Torrero Zelikin's group [[56]] have reported efficient suppression of tumor growth by enzyme prodrug therapy, which takes advantage of noncovalent albumin binding and, subsequently, delivery of the prodrug to the tumor as well as the endogenous enzymatic repertoire of the tumor. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
194. Insight into GEBR-32a: Chiral Resolution, Absolute Configuration and Enantiopreference in PDE4D Inhibition.
- Author
-
Cavalloro, Valeria, Russo, Katia, Vasile, Francesca, Pignataro, Luca, Torretta, Archimede, Donini, Stefano, Semrau, Marta S., Storici, Paola, Rossi, Daniela, Rapetti, Federica, Brullo, Chiara, Parisini, Emilio, Bruno, Olga, and Collina, Simona
- Subjects
- *
RESOLUTION (Chemistry) , *CHIRAL stationary phases , *CYCLIC adenylic acid , *NUCLEAR magnetic resonance , *AMYLOSE , *ALZHEIMER'S disease , *MEMORY loss - Abstract
Alzheimer's disease is the most common type of dementia, affecting millions of people worldwide. One of its main consequences is memory loss, which is related to downstream effectors of cyclic adenosine monophosphate (cAMP). A well-established strategy to avoid cAMP degradation is the inhibition of phosphodiesterase (PDE). In recent years, GEBR-32a has been shown to possess selective inhibitory properties against PDE type 4 family members, resulting in an improvement in spatial memory processes without the typical side effects that are usually correlated with this mechanism of action. In this work, we performed the HPLC chiral resolution and absolute configuration assignment of GEBR-32a. We developed an efficient analytical and semipreparative chromatographic method exploiting an amylose-based stationary phase, we studied the chiroptical properties of both enantiomers and we assigned their absolute configuration by 1H-NMR (nuclear magnetic resonance). Lastly, we measured the IC50 values of both enantiomers against both the PDE4D catalytic domain and the long PDE4D3 isoform. Results strongly support the notion that GEBR-32a inhibits the PDE4D enzyme by interacting with both the catalytic pocket and the regulatory domains. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
195. Computational Methods for the Discovery and Optimization of TAAR1 and TAAR5 Ligands.
- Author
-
Scarano N, Espinoza S, Brullo C, and Cichero E
- Subjects
- Ligands, Humans, Animals, Molecular Docking Simulation, Protein Binding, Receptors, G-Protein-Coupled metabolism, Receptors, G-Protein-Coupled chemistry, Drug Discovery methods
- Abstract
G-protein-coupled receptors (GPCRs) represent a family of druggable targets when treating several diseases and continue to be a leading part of the drug discovery process. Trace amine-associated receptors (TAARs) are GPCRs involved in many physiological functions with TAAR1 having important roles within the central nervous system (CNS). By using homology modeling methods, the responsiveness of TAAR1 to endogenous and synthetic ligands has been explored. In addition, the discovery of different chemo-types as selective murine and/or human TAAR1 ligands has helped in the understanding of the species-specificity preferences. The availability of TAAR1-ligand complexes sheds light on how different ligands bind TAAR1. TAAR5 is considered an olfactory receptor but has specific involvement in some brain functions. In this case, the drug discovery effort has been limited. Here, we review the successful computational efforts developed in the search for novel TAAR1 and TAAR5 ligands. A specific focus on applying structure-based and/or ligand-based methods has been done. We also give a perspective of the experimental data available to guide the future drug design of new ligands, probing species-specificity preferences towards more selective ligands. Hints for applying repositioning approaches are also discussed.
- Published
- 2024
- Full Text
- View/download PDF
196. PDE4D: A Multipurpose Pharmacological Target.
- Author
-
Lusardi M, Rapetti F, Spallarossa A, and Brullo C
- Subjects
- Humans, Animals, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases metabolism, Neoplasms drug therapy, Neoplasms metabolism, Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism, Phosphodiesterase 4 Inhibitors pharmacology, Phosphodiesterase 4 Inhibitors therapeutic use, Phosphodiesterase 4 Inhibitors chemistry
- Abstract
Phosphodiesterase 4 (PDE4) enzymes catalyze cyclic adenosine monophosphate (cAMP) hydrolysis and are involved in a variety of physiological processes, including brain function, monocyte and macrophage activation, and neutrophil infiltration. Among different PDE4 isoforms, Phosphodiesterases 4D (PDE4Ds) play a fundamental role in cognitive, learning and memory consolidation processes and cancer development. Selective PDE4D inhibitors (PDE4Dis) could represent an innovative and valid therapeutic strategy for the treatment of various neurodegenerative diseases, such as Alzheimer's, Parkinson's, Huntington's, and Lou Gehrig's diseases, but also for stroke, traumatic brain and spinal cord injury, mild cognitive impairment, and all demyelinating diseases such as multiple sclerosis. In addition, small molecules able to block PDE4D isoforms have been recently studied for the treatment of specific cancer types, particularly hepatocellular carcinoma and breast cancer. This review overviews the PDE4DIsso far identified and provides useful information, from a medicinal chemistry point of view, for the development of a novel series of compounds with improved pharmacological properties.
- Published
- 2024
- Full Text
- View/download PDF
197. Amelioration of functional and histopathological consequences after spinal cord injury through phosphodiesterase 4D (PDE4D) inhibition.
- Author
-
Schepers M, Hendrix S, Mussen F, van Breedam E, Ponsaerts P, Lemmens S, Hellings N, Ricciarelli R, Fedele E, Bruno O, Brullo C, Prickaerts J, Van Broeckhoven J, and Vanmierlo T
- Subjects
- Animals, Recovery of Function drug effects, Recovery of Function physiology, Mice, Female, Aminopyridines pharmacology, Aminopyridines therapeutic use, Mice, Inbred C57BL, Humans, Cyclic AMP metabolism, Benzamides, Cyclopropanes, Spinal Cord Injuries drug therapy, Spinal Cord Injuries pathology, Spinal Cord Injuries metabolism, Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism, Phosphodiesterase 4 Inhibitors pharmacology, Phosphodiesterase 4 Inhibitors therapeutic use
- Abstract
Spinal cord injury (SCI) is a life-changing event that severely impacts the patient's quality of life. Modulating neuroinflammation, which exacerbates the primary injury, and stimulating neuro-regenerative repair mechanisms are key strategies to improve functional recovery. Cyclic adenosine monophosphate (cAMP) is a second messenger crucially involved in both processes. Following SCI, intracellular levels of cAMP are known to decrease over time. Therefore, preventing cAMP degradation represents a promising strategy to suppress inflammation while stimulating regeneration. Intracellular cAMP levels are controlled by its hydrolyzing enzymes phosphodiesterases (PDEs). The PDE4 family is most abundantly expressed in the central nervous system (CNS) and its inhibition has been shown to be therapeutically relevant for managing SCI pathology. Unfortunately, the use of full PDE4 inhibitors at therapeutic doses is associated with severe emetic side effects, hampering their translation toward clinical applications. Therefore, in this study, we evaluated the effect of inhibiting specific PDE4 subtypes (PDE4B and PDE4D) on inflammatory and regenerative processes following SCI, as inhibitors selective for these subtypes have been demonstrated to be well-tolerated. We reveal that administration of the PDE4D inhibitor Gebr32a, even when starting 2 dpi, but not the PDE4B inhibitor A33, improved functional as well as histopathological outcomes after SCI, comparable to results obtained with the full PDE4 inhibitor roflumilast. Furthermore, using a luminescent human iPSC-derived neurospheroid model, we show that PDE4D inhibition stabilizes neural viability by preventing apoptosis and stimulating neuronal differentiation. These findings strongly suggest that specific PDE4D inhibition offers a novel therapeutic approach for SCI., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MS, JP, and TV have a proprietary interest in selective PDE4D inhibitors for the treatment of demyelinating disorders and neurodegenerative disorders. RR, EF, OB, CB, and JP have a proprietary interest in the use of Gebr32a. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
198. A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo-Pyrazole Treatment in SKMEL-28 Melanoma Cells.
- Author
-
Iervasi E, Coronel Vargas G, Bachetti T, Tkachenko K, Spallarossa A, Brullo C, Rosano C, Carta S, Barboro P, Profumo A, and Ponassi M
- Subjects
- Humans, Cell Line, Tumor, Transcription Factors metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Skin Neoplasms drug therapy, Skin Neoplasms metabolism, Skin Neoplasms pathology, DNA-Binding Proteins metabolism, Imidazoles pharmacology, Imidazoles chemistry, Gene Expression Regulation, Neoplastic drug effects, Proteome metabolism, Melanoma drug therapy, Melanoma metabolism, Melanoma pathology, Pyrazoles pharmacology, Pyrazoles chemistry, Proteomics methods
- Abstract
Cutaneous melanoma is the most dangerous and deadly form of human skin malignancy. Despite its rarity, it accounts for a staggering 80% of deaths attributed to cutaneous cancers overall. Moreover, its final stages often exhibit resistance to drug treatments, resulting in unfavorable outcomes. Hence, ensuring access to novel and improved chemotherapeutic agents is imperative for patients grappling with this severe ailment. Pyrazole and its fused systems derived thereof are heteroaromatic moieties widely employed in medicinal chemistry to develop effective drugs for various therapeutic areas, including inflammation, pain, oxidation, pathogens, depression, and fever. In a previous study, we described the biochemical properties of a newly synthesized group of imidazo-pyrazole compounds. In this paper, to improve our knowledge of the pharmacological properties of these molecules, we conduct a differential proteomic analysis on a human melanoma cell line treated with one of these imidazo-pyrazole derivatives. Our results detail the changes to the SKMEL-28 cell line proteome induced by 24, 48, and 72 h of 3e imidazo-pyrazole treatment. Notably, we highlight the down-regulation of the Ras-responsive element binding protein 1 (RREB1), a member of the zinc finger transcription factors family involved in the tumorigenesis of melanoma. RREB1 is a downstream element of the MAPK pathway, and its activation is mediated by ERK1/2 through phosphorylation.
- Published
- 2024
- Full Text
- View/download PDF
199. Anticancer Effects of the Novel Pyrazolyl-Urea GeGe-3.
- Author
-
Williams A, Cooper E, Clark B, Perry L, Ponassi M, Iervasi E, Brullo C, Greenhough A, and Ladomery M
- Subjects
- Humans, Cell Line, Tumor, Urea pharmacology, Urea chemistry, Urea analogs & derivatives, Pyrazoles pharmacology, Pyrazoles chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Cell Movement drug effects
- Abstract
In a screen of over 200 novel pyrazole compounds, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl)ureido)-1 H -pyrazole-4-carboxylate (named GeGe-3) has emerged as a potential anticancer compound. GeGe-3 displays potent anti-angiogenic properties through the presumptive targeting of the protein kinase DMPK1 and the Ca2
+ -binding protein calreticulin. We further explored the anticancer potential of GeGe-3 on a range of established cancer cell lines, including PC3 (prostate adenocarcinoma), SKMEL-28 (cutaneous melanoma), SKOV-3 (ovarian adenocarcinoma), Hep-G2 (hepatocellular carcinoma), MDA-MB231, SKBR3, MCF7 (breast adenocarcinoma), A549 (lung carcinoma), and HeLa (cervix epithelioid carcinoma). At concentrations in the range of 10 μM, GeGe-3 significantly restricted cell proliferation and metabolism. GeGe-3 also reduced PC3 cell migration in a standard wound closure and trans-well assay. Together, these results confirm the anticancer potential of GeGe-3 and underline the need for more detailed pre-clinical investigations into its molecular targets and mechanisms of action.- Published
- 2024
- Full Text
- View/download PDF
200. Investigations of Antioxidant and Anti-Cancer Activities of 5-Aminopyrazole Derivatives.
- Author
-
Rapetti F, Spallarossa A, Russo E, Caviglia D, Villa C, Tasso B, Signorello MG, Rosano C, Iervasi E, Ponassi M, and Brullo C
- Subjects
- Humans, Structure-Activity Relationship, Cell Line, Tumor, Cell Proliferation drug effects, Molecular Structure, Pyrazoles chemistry, Pyrazoles pharmacology, Pyrazoles chemical synthesis, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antioxidants pharmacology, Antioxidants chemistry
- Abstract
To further extend the structure-activity relationships (SARs) of 5-aminopyrazoles (5APs) and identify novel compounds able to interfere with inflammation, oxidative stress, and tumorigenesis, 5APs 1-4 have been designed and prepared. Some chemical modifications have been inserted on cathecol function or in aminopyrazole central core; in detail: (i) smaller, bigger, and more lipophilic substituents were introduced in meta and para positions of catechol portion (5APs 1 ); (ii) a methyl group was inserted on C3 of the pyrazole scaffold (5APs 2 ); (iii) a more flexible alkyl chain was inserted on N1 position (5APs 3 ); (iv) the acylhydrazonic linker was moved from position 4 to position 3 of the pyrazole scaffold (5APs 4 ). All new derivatives 1-4 have been tested for radical scavenging (DPPH assay), anti-aggregating/antioxidant (in human platelets) and cell growth inhibitory activity (MTT assay) properties. In addition, in silico pharmacokinetics, drug-likeness properties, and toxicity have been calculated. 5APs 1 emerged to be promising anti-proliferative agents, able to suppress the growth of specific cancer cell lines. Furthermore, derivatives 3 remarkably inhibited ROS production in platelets and 5APs 4 showed interesting in vitro radical scavenging properties. Overall, the collected results further confirm the pharmaceutical potentials of this class of compounds and support future studies for the development of novel anti-proliferative and antioxidant agents.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.